SCHEMBL31240560

SCHEMBL31240560

Nc1n[nH]c2ccc(-c3ccnc4[nH]c(-c5cc(F)nc(CNc6ccccc6)c5)cc34)cc12

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CLK2 P49760 9/20 0.44
▸ DYRK1A Q13627 9/20 0.44
▸ CLK3 P49761 7/20 0.44
▸ EGFR P00533 7/20 0.41
▸ MAPK14 Q16539 4/20 0.41
▸ JAK2 O60674 2/20 0.39
▸ JAK1 P23458 1/20 0.38
▸ TYK2 P29597 1/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ CDC7 O00311 1/20 0.38
▸ CCNE1 P24864 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ DBF4 Q9UBU7 1/20 0.38
▸ WNT1 P04628 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31240389 0.86 CLK2 (0.42) CLK2DYRK1ACLK3EGFRJAK2
SCHEMBL31240648 0.85 TRPA1 (0.41) CLK2DYRK1ACLK3EGFRMAPK14
SCHEMBL31240412 0.85 CLK2 (0.51) CLK2DYRK1ACLK3EGFRMAPK14
SCHEMBL31240570 0.83 DYRK1A (0.48) CLK2DYRK1ACLK3EGFRJAK2
SCHEMBL31240504 0.83 DYRK1A (0.40) CLK2DYRK1ACLK3MAPK14WNT1
SCHEMBL31240490 0.81 CLK2 (0.47) CLK2DYRK1ACLK3EGFRMAPK14
SCHEMBL26685816 0.81 JAK2 (0.47) CLK2DYRK1ACLK3JAK2JAK1
SCHEMBL31240594 0.81 DYRK1A (0.44) CLK2DYRK1ACLK3EGFRMAPK14
SCHEMBL31240405 0.80 CLK2 (0.59) CLK2DYRK1ACLK3EGFRMAPK14
SCHEMBL31240586 0.80 CLK2 (0.52) CLK2DYRK1ACLK3EGFRJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP disclosed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO disclosed
Send feedback